The short version of Tesamorelin fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-22 and is reviewed periodically as new material appears.
Metabolic interest in this compound centers on fat distribution rather than on hormone levels alone. Imaging trials in adults with excess abdominal fat report reductions in visceral adipose tissue, while subcutaneous depots change comparatively little. Growth hormone and IGF-1 are presumed to carry the effect, but the separate contribution of each is not firmly established. Whether these changes persist after treatment stops, and whether they alter longer-term health outcomes, remain open questions that published work does not answer consistently.
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 44-residue peptide | GHRH analog backbone |
| Approximate molecular mass | 5136 Da | Varies with counterion and hydration state |
| N-terminal group | trans-3-hexenoyl | Increases resistance to dipeptidyl peptidase IV |
| Primary receptor | GHRH receptor (GHRHR) | Class B G protein-coupled receptor on somatotrophs |
| Principal mediator | IGF-1 | Rises indirectly after growth hormone release |
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
=== Ancient pharmacology === Using plants and plant substances to treat all kinds of diseases and medical conditions is believed to date back to prehistoric medicine. The Kahun Gynaecological Papyrus, the oldest known medical text of any kind, dates to about 1800 BC and represents the first documented use of any kind of drug. It and other medical papyri describe Ancient Egyptian medical practices, such as using honey to treat infections and the legs of bee-eaters to treat neck pains. Ancient Babylonian medicine demonstrated the use of medication in the first half of the 2nd millennium BC. Medicinal creams and pills were employed as treatments. On the Indian subcontinent, the Atharvaveda, a sacred text of Hinduism whose core dates from the second millennium BC, although the hymns recorded in it are believed to be older, is the first Indic text dealing with medicine. It describes plant-based drugs to counter diseases. The earliest foundations of ayurveda were built on a synthesis of selected ancient herbal practices, together with a massive addition of theoretical conceptualizations, new nosologies and new therapies dating from about 400 BC onwards. The student of Āyurveda was expected to know ten arts that were indispensable in the preparation and application of his medicines: distillation, operative skills, cooking, horticulture, metallurgy, sugar manufacture, pharmacy, analysis and separation of minerals, compounding of metals, and preparation of alkalis.
In spring 2026, the European Parliament and the Council of the European Union defined a relative potency factor (RPF) of 0.002 perfluorooctanoic acid (PFOA) equivalents for TFA, while a threshold of 0.0044 µg/L PFOA equivalents for the sum of 25 PFAS (now including TFA) in inland surface water was set.
Bats possess a highly adapted respiratory system to cope with the demands of powered flight. They have relatively large lungs, and many species have proportionally larger alveolar surface areas and pulmonary capillary blood volumes than other mammals. During flight, the respiratory cycle has a one-to-one relationship with the wing-beat cycle. Their mammalian lungs prevent them from flying at high altitudes. Bats can also meet oxygen demands by exchanging gas through the patagium of the wing. When the bat has its wings spread, it allows for an increase in surface area to volume ratio, 85% of the surface area being the wing. The subcutaneous vessels in the membrane lie near the surface and allow for the diffusion of oxygen and carbon dioxide. The digestive system of bats varies depending on the species of bat and its diet. Digestion is relatively quick to meet the energy demands of flight. Insectivorous bats may have certain digestive enzymes to better process insects, such as chitinase to break down their chitin exoskeleton. Vampire bats, probably due to their diet of blood, are unique among vertebrates in that they do not have the enzyme maltase, which breaks down malt sugar, in their intestinal tract. Nectivorous and frugivorous bats have more maltase and sucrase enzymes than insectivores, to cope with the higher sugar contents of their diet. The adaptations of the kidneys of bats vary with their diets. Carnivorous and vampire bats consume large amounts of protein and can output concentrated urine; their kidneys have a thin cortex and long renal papillae.
Hydroxyzine, sold under the brand names Atarax (as hydrochloride) and Vistaril (as pamoate) among others, is an antihistamine medication. It is used in the treatment of itchiness, anxiety, insomnia, and nausea (including that due to motion sickness). It is used either by mouth or injection into a muscle. Hydroxyzine works by blocking the effects of histamine. It is a first-generation antihistamine in the piperazine family of chemicals. Common side effects include sleepiness, headache, and dry mouth. Serious side effects may include QT prolongation. It is unclear if use during pregnancy or breastfeeding is safe. It was first made by Union Chimique Belge in 1956 and was approved for sale by Pfizer in the United States later that year. In 2023, it was the 39th most commonly prescribed medication in the United States, with more than 15 million prescriptions.
==== Charitable contributions tax deduction ==== Effective January 1, 2026, the law allows a tax deduction for charitable contributions made in cash by an individual who does not itemize their tax deductions. The deduction is limited to $1,000 (or $2,000 if married filing jointly). The deduction is not allowed for contributions to donor-advised funds or private non-operating foundations. Carrying over excess charitable contributions to other years is not allowed if the person does not itemize their tax deductions. Effective January 1, 2026, for individuals who itemize their tax deductions, a tax deduction is allowed only for the amount that exceeds 0.5 percent of their adjusted gross income. The law makes permanent a temporary limit on cash tax deductions for charitable contributions of up to 60 percent of their adjusted gross income to 501(c)(3) public charities. This only applies if the individual itemizes their tax deductions. Effective January 1, 2026, the tax benefit for charitable contributions made by an individual that itemizes their tax deductions is limited to 35% of the amount contributed, even if they are in a marginal tax bracket higher than 35%.
Sources: en.wikipedia.org
Greenland's prime minister Jens-Frederik Nielsen thanked the European allies for their support. Ursula von der Leyen said in a speech at the World Economic Forum on 20 January that geopolitical "shocks" and Trump's worldview require a "new form of European independence." She underlined that the sovereignty and integrity of the Kingdom of Denmark including Greenland is non-negotiable. Hungarian Foreign Minister Péter Szijjártó stated that the EU does not need to deal with the Greenland crisis because it is only a dispute between Denmark and the US. There have been claims that Hungary and Prime Minister Viktor Orbán have provided behind the scenes support for Donald Trump's territorial claims concerning Greenland. At the same time, Szijjártó's statement violates several obligations and expectations associated with EU membership, given that Denmark is also a member of the EU. At the height of the crisis, there also emerged calls and petitions to boycott the 2026 FIFA World Cup, planned for the next summer and co-hosted by the United States. On 6 February, France and Canada announced the opening of their respective consulates in Nuuk in support of Greenlanders.
More potential nutrients from the grape must (though the bacteria will be competing with the yeast for these) Lower sulfur dioxide and ethanol levels which can otherwise inhibit the LAB Higher fermentation temperatures which are more conducive to LAB growth and an earlier completion of MLF: The optimal temperatures for malolactic fermentation are between 20 and 37 °C (68 and 99 °F), while the process is significantly inhibited at temperatures below 15 °C (59 °F). Wine stored in the barrels in the cellar during the winter following fermentation will often have a very prolonged malolactic fermentation due to the cool cellar temperatures. Early completion of malolactic fermentation means the winemaker can make a postfermentation SO2 earlier to protect the wine from oxidation and spoilage microbes (such as Acetobacter). Since sulfur dioxide can inhibit MLF, delaying LAB inoculation till after alcoholic fermentation may mean a delay in sulfur addition till early spring when cellar temperatures warm up enough to encourage the completion of MLF. Less diacetyl production The disadvantages for early inoculation include:
==== Louis Vuitton fashion shows ==== Williams was hand-selected to be the new creative director of menswear at luxury fashion house Louis Vuitton in 2023. In a story with the New York Times about the job and his upcoming debut fashion show with the brand, an unheard song with Pusha T ("Chains & Whips") was teased, although it was not yet revealed as a Clipse song. The three annual spring–summer shows from this point until Let God Sort Em Out's release all featured new Clipse music in their soundtracks, along with other songs. "Chains & Whips" was debuted at the Louis Vuitton's Men's Spring–Summer Show 2024 on June 20, 2023, although Kendrick Lamar's guest verse was not yet included. Pusha T and Malice also walked on the runway in Williams's designs. For the Men's Spring–Summer Show 2025 on June 18, 2024, "The Birds Don't Sing" was previewed for the first time, featuring vocals by John Legend. The Men's Spring–Summer Show 2026 debuted "So Be It Pt. II" on June 24, 2025.
The structure of the AG glycans consists of a backbone of β-1,3 linked galactose (Gal), with sidechains of β-1,6 linked Gal and have terminal residues of arabinose (Ara), rhamnose (Rha), Gal, fucose (Fuc), and glucuronic acid (GlcA). These AG glycan moieties are assembled by glycosyltransferases (GTs). O-glycosylation of AGPs is initiated by the action of Hyp-O-galactosyltransferases (Hyp-O-GalTs) that add the first Gal onto the protein. The complex glycan structures are then elaborated by a suite of glycosyltransferases, the majority of which are bio-chemically uncharacterized. The GT31 family is one of the families involved in AGP glycan backbone biosynthesis. Numerous members of the GT31 family have been identified with Hyp-O-GALT activity and the core β-(1,3)-galactan backbone is also likely to be synthesized by the GT31 family. Members of the GT14 family are implicated in adding β-(1,6)- and β-(1,3)-galactans to AGPs. In Arabidopsis, terminal sugars such as fucose are proposed to be added by AtFUT4 (a fucosyl transferase) and AtFUT6 in the GT37 family and the terminal GlcA incorporation can be catalysed by the GT14 family. A number of GTs remain to be identified, for example those responsible for terminal Rha.
Sources: en.wikipedia.org
The amino acid sequence matches human growth hormone-releasing hormone, but the amino terminus carries a trans-3-hexenoyl group instead of a free amine. That single structural change chiefly affects enzymatic stability rather than receptor selectivity.
Growth hormone released from the pituitary stimulates IGF-1 production in the liver and other tissues, so circulating IGF-1 generally rises during exposure. The size of the rise varies between individuals and depends on baseline hormonal status and other concurrent factors.
Reported imaging studies focus on visceral adipose tissue, where reductions are more consistently observed across trials. Subcutaneous depots show smaller and less reproducible changes, so the two compartments should not be treated as equivalent.
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.